search
Back to results

Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock (KETO-SHOCK1)

Primary Purpose

Cardiogenic Shock

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
KetoneAid Ketone Ester
Maltodextrin
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiogenic Shock focused on measuring Ketone bodies, β-hydroxybutyrate

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ongoing treatment with inotropes and/or vasopressors because of cardiogenic shock as judged by the clinicians
  • Patients are required at some point in time to have had > 1 of the following: systolic blood pressure < 90 mmHg; arterial blood lactate ≥ 2.5mmol/l; organ hypoperfusion (e.g. urinary output < 0.5 ml/kg/hour or SvO2 <55% with normal PaO2 and Hgb)
  • LVEF < 40%
  • Age ≥ 18 years

Exclusion Criteria:

  • Other primary causes of shock (hypovolemia, hemorrhage, severe infection or sepsis, pulmonary embolism or anaphylaxis),
  • Shock due to mechanical complication to myocardial infarction (papillary muscle rupture, rupture of the ventricular septum or rupture of free wall)
  • INTERMACS level 1 or 2 [18] with unstable or sliding hemodynamics on inotropes/vasopressors
  • Use of or probable need for mechanic circulatory support (e.g. left ventricular assistant device, IMPELLA, extracorporeal membrane oxygenation)
  • Recent post-cardiotomy cardiogenic shock (defined as thoracic surgery with the last 3 days)
  • Inability to position a nasogastric tube
  • Severe gastroparesis or abdominal distension

Sites / Locations

  • Aarhus University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

3-Hydroxybutyrate treatment

Placebo Treatment

Arm Description

KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus

Maltodextrin-base isocaloric placebo

Outcomes

Primary Outcome Measures

Cardiac Output (L/min) area under curve
Right Heart Catheterization (by thermodilution)

Secondary Outcome Measures

Cardiac output (L/min)
Right Heart Catheterization (by thermodilution)
Left Ventricular Filling Pressure (mmHg) area under curve
Right Heart Catheterization
Cardiac Power Output (W) area under curve
mean arterial pressure x cardiac output/451
Mixed Venous Saturation (%) area under curve
Right Heart Catheterization
Left Ventricular Ejection Fraction (%) area under curve
Echocardiography
Hourly urinary output (mL/hour) area under curve
Renal Perfusion (mL/min)
Renal doppler ultrasound
Arterial Lactate (mmol/L) area under curve
Arterial blood gas measurements
Cumulative doses of inotropes and vasopressors during the 3 hour studyperiod
Cerebral Perfusion area under curve
Near-infrared spectroscopy
Peripheral Perfusion area under curve
Near-infrared spectroscopy

Full Information

First Posted
November 18, 2020
Last Updated
May 18, 2022
Sponsor
University of Aarhus
search

1. Study Identification

Unique Protocol Identification Number
NCT04642768
Brief Title
Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock
Acronym
KETO-SHOCK1
Official Title
Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
May 17, 2022 (Actual)
Study Completion Date
May 17, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Aarhus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background Cardiogenic shock is a life-threatening state of acute heart failure with severely depressed blood pressure and organ perfusion. The 30-day mortality is reported as high as 50%. To date, no randomized trial has documented a survival benefit of any medical treatment in this patient group. In a first-in-man study the investigators have recently discovered that treatment with ketone bodies increases cardiac output by 2 liters per minute. Objective The present study aims to examine the direct effects of ketone body supplements on the heart function in patients hospitalized with cardiogenic shock. Also, the aim is to determine the relative need for medical circulatory support following ketone body supplement. Design A randomized double-blind cross-over study of the hemodynamic effect of enteral ketone ester versus placebo in 12 patients with cardiogenic shock Methods Right heart catheterization will be installed to monitor cardiac pressures and output. The investigators will observe heart function with transthoracic echocardiography. Blood- and urine samples will be analyzed for electrolytes, energy substrates and vasoactive substances. Organ perfusion is to be examined by renal ultrasonography and near-infrared spectroscopy for measuring cerebral and peripheral circulation. Perspectives This investigation may grant essential knowledge on ketosis in cardiogenic shock. This may lead to larger clinical trials, and hopefully a new and better treatment for patients with cardiogenic shock.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiogenic Shock
Keywords
Ketone bodies, β-hydroxybutyrate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
3-Hydroxybutyrate treatment
Arm Type
Experimental
Arm Description
KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
Arm Title
Placebo Treatment
Arm Type
Placebo Comparator
Arm Description
Maltodextrin-base isocaloric placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
KetoneAid Ketone Ester
Intervention Description
Commercially available ketone supplement
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin
Intervention Description
Commercially available maltodextrin supplement
Primary Outcome Measure Information:
Title
Cardiac Output (L/min) area under curve
Description
Right Heart Catheterization (by thermodilution)
Time Frame
3 hours
Secondary Outcome Measure Information:
Title
Cardiac output (L/min)
Description
Right Heart Catheterization (by thermodilution)
Time Frame
1 hour
Title
Left Ventricular Filling Pressure (mmHg) area under curve
Description
Right Heart Catheterization
Time Frame
3 hours
Title
Cardiac Power Output (W) area under curve
Description
mean arterial pressure x cardiac output/451
Time Frame
3 hours
Title
Mixed Venous Saturation (%) area under curve
Description
Right Heart Catheterization
Time Frame
3 hours
Title
Left Ventricular Ejection Fraction (%) area under curve
Description
Echocardiography
Time Frame
3 hours
Title
Hourly urinary output (mL/hour) area under curve
Time Frame
3 hours
Title
Renal Perfusion (mL/min)
Description
Renal doppler ultrasound
Time Frame
1 hours
Title
Arterial Lactate (mmol/L) area under curve
Description
Arterial blood gas measurements
Time Frame
3 hours
Title
Cumulative doses of inotropes and vasopressors during the 3 hour studyperiod
Time Frame
3 hours
Title
Cerebral Perfusion area under curve
Description
Near-infrared spectroscopy
Time Frame
3 hours
Title
Peripheral Perfusion area under curve
Description
Near-infrared spectroscopy
Time Frame
3 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ongoing treatment with inotropes and/or vasopressors because of cardiogenic shock as judged by the clinicians Patients are required at some point in time to have had > 1 of the following: systolic blood pressure < 90 mmHg; arterial blood lactate ≥ 2.5mmol/l; organ hypoperfusion (e.g. urinary output < 0.5 ml/kg/hour or SvO2 <55% with normal PaO2 and Hgb) LVEF < 40% Age ≥ 18 years Exclusion Criteria: Other primary causes of shock (hypovolemia, hemorrhage, severe infection or sepsis, pulmonary embolism or anaphylaxis), Shock due to mechanical complication to myocardial infarction (papillary muscle rupture, rupture of the ventricular septum or rupture of free wall) INTERMACS level 1 or 2 [18] with unstable or sliding hemodynamics on inotropes/vasopressors Use of or probable need for mechanic circulatory support (e.g. left ventricular assistant device, IMPELLA, extracorporeal membrane oxygenation) Recent post-cardiotomy cardiogenic shock (defined as thoracic surgery with the last 3 days) Inability to position a nasogastric tube Severe gastroparesis or abdominal distension
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
State/Province
Midtjylland
ZIP/Postal Code
8200
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock

We'll reach out to this number within 24 hrs